Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603457 | PMC |
| http://dx.doi.org/10.2105/AJPH.2019.305118 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.
Lancet Oncol
October 2024
Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA.
Background: Capmatinib has previously shown activity in treatment-naive and previously treated patients with non-small-cell lung cancer (NSCLC) and a MET exon 14-skipping mutation (METex14). Here, we report the final outcomes from the phase 2 GEOMETRY mono-1 study with an aim to provide further evidence for the activity of capmatinib.
Methods: In this non-randomised, multi-cohort, open-label, phase 2 trial conducted in 152 centres and hospitals in 25 countries, with patients treated in 95 centres in 20 countries, eligible patients (aged ≥18 years) with MET-dysregulated, EGFR wild-type, and ALK rearrangement-negative advanced NSCLC (stage IIIB/IV) and an Eastern Cooperative Oncology Group performance status of 0 or 1 were assigned to cohorts (1a, 1b, 2, 3, 4, 5a, 5b, 6 and 7) based on their MET status (METex14 or MET amplification) and previous therapy lines.
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.
J Exp Med
October 2024
Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Identifying pan-tumor biomarkers that predict responses to immune checkpoint inhibitors (ICI) is critically needed. In the AMADEUS clinical trial (NCT03651271), patients with various advanced solid tumors were assessed for changes in intratumoral CD8 percentages and their response to ICI. Patients were grouped based on tumoral CD8 levels: those with CD8 <15% (CD8-low) received nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA4) and those with CD8 ≥15% (CD8-high) received nivolumab monotherapy.
View Article and Find Full Text PDFEvidence and policy is certainly more complex than it seems.
Addiction
November 2024
Faculty of Medicine, School of Public Health, The University of Queensland, Brisbane, Australia.
E-cigarettes: A framework for comparative history and policy.
Addiction
November 2024
Mailman School of Public Health, Columbia University, New York, NY, USA.
Background: England, Australia and the United States have approached the regulation of e-cigarettes in very different ways, yet all three countries have appealed to the concept of evidence as underpinning policy responses. We compared these policy responses using a combination of the methodologies of historians and policy scientists in order to elucidate the factors that had influenced policy in each country.
Argument/analysis: Each country's evidence and values intersected in different ways, producing very different responses within specific national contexts and histories.
Associations of Sex, Race, and Apolipoprotein E Alleles With Multiple Domains of Cognition Among Older Adults.
JAMA Neurol
September 2023
Vanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Article Synopsis
- The study investigates how sex and race influence the relationship between apolipoprotein E (APOE) alleles (ε4 and ε2) and cognitive function in Alzheimer’s disease (AD) across different populations.
- Using data from four cohorts of older adults (60+ years) who self-identified as either non-Hispanic White or non-Hispanic Black, researchers analyzed cognitive outcomes related to memory and executive function.
- Findings suggest significant differences in how APOE ε4 impacts cognitive scores based on sex, with the interactions varying by race, indicating that genetic factors influencing cognition in AD are complex and multifaceted.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!